Humacyte
HUMA
75 hedge funds and large institutions have $25.1M invested in Humacyte in 2022 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 33 increasing their positions, 14 reducing their positions, and 10 closing their positions.
136% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 14
60% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 10
7% more funds holding
Funds holding: 70 → 75 (+5)
0.08% more ownership
Funds ownership: 11.51% → 11.59% (+0.08%)
6% less call options, than puts
Call options by funds: $32K | Put options by funds: $34K
35% less capital invested
Capital invested by funds: $38.7M → $25.1M (-$13.6M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.46M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$833K |
| 3 |
Bank of New York Mellon
New York
|
+$601K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$587K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$529K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YCMGA
York Capital Management Global Advisors
New York
|
-$4.56M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$1.94M |
| 3 |
Millennium Management
New York
|
-$1.38M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$628K |
| 5 |
Renaissance Technologies
New York
|
-$559K |
HUMA Hedge Fund Activity: Q4 2022 in Review
75 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q4 2022, worth a combined $25.1M — down 35% from $38.7M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new HUMA positions and 10 closed out — a net gain of 6 holders — while 33 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $5.46M. The largest seller was York Capital Management Global Advisors, exiting entirely with an estimated $4.56M sold.
- 75 institutional investors held Humacyte (HUMA) as of Q4 2022, up from 70 in Q3 2022.
- Funds reported $25.1M of Humacyte stock for Q4 2022, down 35% quarter-over-quarter.
- 16 funds opened new Humacyte positions in Q4 2022 and 10 closed out, a net change of +6 holders.
- The largest Humacyte buyer in Q4 2022 was BlackRock, an estimated $5.46M added.
- The largest Humacyte seller in Q4 2022 was York Capital Management Global Advisors, an estimated $4.56M sold.
Based on aggregated 13F filings for Q4 2022.